Operator
Good morning, and welcome to the Plus Therapeutics Midyear 2026 Business Update Conference Call. [Operator Instructions]
Before we begin, we want to advise you that over the course of the call and the question-and-answer session, forward-looking statements will be made regarding events, trends, business prospects and financial performance, which may affect Plus Therapeutics’ future operating results and financial position. All such statements are subject to risks and uncertainties, including those described in Plus Therapeutics’ annual report on Form 10-K and quarterly reports on Form 10-Q. Plus Therapeutics advises you to review these risk factors in considering such statements.
In addition, comments made during this conference call contain information that is accurate as of the date of the live broadcast today, June 30, 2026. Plus Therapeutics assumes no responsibility to update or revise any statements to reflect events, trends or circumstances after the date they are made, except as required by law.
It is now my pleasure to turn the call over to Dr. Marc Hedrick, Plus Therapeutics’ President and Chief Executive Officer. Dr. Hedrick, you may begin.
Marc Hedrick
President, CEO & Director
Thank you, Betsy. Good morning, and thank you for joining today’s call. Let me begin with some important and exciting news. We are pleased to announce that Plus Therapeutics is becoming Cerenome. We will begin trading on NASDAQ under a new ticker CNSY, beginning on August 3. Shareholders do not need to
Credit: Source link
